ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.
OBJECTIVE
Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke. In this study, we evaluated the relationship between the extent of adenosine diphosphate (ADP)-induced platelet aggregation and outcome in acute ischemic stroke patients on aspirin therapy.


METHODS
We selected 107 acute ischemic stroke patients who had been prescribed aspirin and evaluated platelet function test by using optic platelet aggregometer test after 5 days of taking it and investigated the prognosis 90 days after ischemic events. Kaplan-Meyer curve was used for survival analysis.


RESULTS
After stratification of the subjected patients by tertiles of ADP-induced platelet aggregation, the events rates were 7.4%, 9.3% and 30.8% (P = 0.023). In multiple logistic regression analysis, old age over 70 years (OR, 13.7; 95% CI, 2.14-88.07; P = 0.001) and the increased ADP-induced platelet aggregation had independent significance to the risk of primary end-points after acute ischemic stroke (OR, 1.1; 95% CI 1.01 to 1.20; P = 0.026).


CONCLUSIONS
This study showed that the increased ADP-induced platelet aggregation under using aspirin is associated with poor outcome after acute ischemic stroke.
Cha
J-K
JK
Department of Neurology, College of Medicine, Dong-A University, Dongdaeshin-Dong, Busan, South Korea. nrcjk@unitel.co.kr
Jeon
H-W
HW
Kang
M-J
MJ
D000208:Acute Disease; D000244:Adenosine Diphosphate / Q000494:pharmacology*; D000368:Aged; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy*; D000077144:Clopidogrel; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects* / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin